All Stories

  1. Neoadjuvant chemotherapy and bevacizumab for colorectal peritoneal metastases: clinical and translational outcomes of the phase II BEV-IP trial
  2. Data from PI3K and MAPK Signaling Nodes Serve as Divergent Drivers of Phenotypic Plasticity in Cancer-Associated Fibroblasts in Colorectal Cancer
  3. Figure S1 from PI3K and MAPK Signaling Nodes Serve as Divergent Drivers of Phenotypic Plasticity in Cancer-Associated Fibroblasts in Colorectal Cancer
  4. Figure S2 from PI3K and MAPK Signaling Nodes Serve as Divergent Drivers of Phenotypic Plasticity in Cancer-Associated Fibroblasts in Colorectal Cancer
  5. Figure S3 from PI3K and MAPK Signaling Nodes Serve as Divergent Drivers of Phenotypic Plasticity in Cancer-Associated Fibroblasts in Colorectal Cancer
  6. Figure S4 from PI3K and MAPK Signaling Nodes Serve as Divergent Drivers of Phenotypic Plasticity in Cancer-Associated Fibroblasts in Colorectal Cancer
  7. Figure S5 from PI3K and MAPK Signaling Nodes Serve as Divergent Drivers of Phenotypic Plasticity in Cancer-Associated Fibroblasts in Colorectal Cancer
  8. Figure S6 from PI3K and MAPK Signaling Nodes Serve as Divergent Drivers of Phenotypic Plasticity in Cancer-Associated Fibroblasts in Colorectal Cancer
  9. Figure S7 from PI3K and MAPK Signaling Nodes Serve as Divergent Drivers of Phenotypic Plasticity in Cancer-Associated Fibroblasts in Colorectal Cancer
  10. Figure S8 from PI3K and MAPK Signaling Nodes Serve as Divergent Drivers of Phenotypic Plasticity in Cancer-Associated Fibroblasts in Colorectal Cancer
  11. Table S1 from PI3K and MAPK Signaling Nodes Serve as Divergent Drivers of Phenotypic Plasticity in Cancer-Associated Fibroblasts in Colorectal Cancer
  12. Table S10 from PI3K and MAPK Signaling Nodes Serve as Divergent Drivers of Phenotypic Plasticity in Cancer-Associated Fibroblasts in Colorectal Cancer
  13. Table S2 from PI3K and MAPK Signaling Nodes Serve as Divergent Drivers of Phenotypic Plasticity in Cancer-Associated Fibroblasts in Colorectal Cancer
  14. Table S3 from PI3K and MAPK Signaling Nodes Serve as Divergent Drivers of Phenotypic Plasticity in Cancer-Associated Fibroblasts in Colorectal Cancer
  15. Table S4 from PI3K and MAPK Signaling Nodes Serve as Divergent Drivers of Phenotypic Plasticity in Cancer-Associated Fibroblasts in Colorectal Cancer
  16. Table S5 from PI3K and MAPK Signaling Nodes Serve as Divergent Drivers of Phenotypic Plasticity in Cancer-Associated Fibroblasts in Colorectal Cancer
  17. Table S6 from PI3K and MAPK Signaling Nodes Serve as Divergent Drivers of Phenotypic Plasticity in Cancer-Associated Fibroblasts in Colorectal Cancer
  18. Table S7 from PI3K and MAPK Signaling Nodes Serve as Divergent Drivers of Phenotypic Plasticity in Cancer-Associated Fibroblasts in Colorectal Cancer
  19. Table S8 from PI3K and MAPK Signaling Nodes Serve as Divergent Drivers of Phenotypic Plasticity in Cancer-Associated Fibroblasts in Colorectal Cancer
  20. Table S9 from PI3K and MAPK Signaling Nodes Serve as Divergent Drivers of Phenotypic Plasticity in Cancer-Associated Fibroblasts in Colorectal Cancer
  21. Consensus on the definition of locoregional recurrence of colon cancer: protocol for an international Delphi study
  22. Computational simulations of localized injection of a PH-sensitive hydrogel for intraperitoneal drug delivery
  23. Population pharmacokinetics and pharmacodynamics of intraperitoneal aerosolized nanoparticle albumin‐bound paclitaxel (nab‐PTX) and metabolites
  24. PI3K and MAPK Signaling Nodes Serve as Divergent Drivers of Phenotypic Plasticity in Cancer-Associated Fibroblasts in Colorectal Cancer
  25. Hydraulic Conductivity of Tumor Tissue from Human Xenografts
  26. Feasibility and efficacy of electromotive intraperitoneal drug delivery: A hybrid study
  27. Viscoelastic modeling of human colon cancer and surrounding healthy tissue using mechanical indentation
  28. Modeling and ex vivo evaluation of electrostatic precipitation-enhanced intraperitoneal aerosol drug delivery
  29. Clinical Validation of Deep Learning for Real-Time Tissue Oxygenation Estimation Using Spectral Imaging
  30. Multimodal machine learning for staging laparoscopy: a combined image analysis and morphologic tool for the discrimination of peritoneal metastasis
  31. Operating characteristics of nebulizers used for intraperitoneal aerosolized drug delivery
  32. Author Correction: Sequential orthogonal assays for longitudinal and endpoint characterization of three-dimensional spheroids
  33. Prediction of surgical resectability after FOLFIRINOX chemotherapy for borderline resectable and locally advanced pancreatic cancer (PeRFormanCe): a multicenter prospective trial - trial protocol
  34. VSIG4‐Expressing Macrophages Contribute to Antiparasitic and Antimetastatic Responses in the Peritoneal Cavity
  35. Sequential orthogonal assays for longitudinal and endpoint characterization of three-dimensional spheroids
  36. Real-time assessment of graft oxygenation and perfusion using spectral imaging for improved outcome in esophageal cancer surgery
  37. Image-guided patient-specific prediction of interstitial fluid flow and drug transport in solid tumors
  38. Pelophen B is a non-taxoid binding microtubule-stabilizing agent with promising preclinical anticancer properties
  39. Pathophysiology of Peritoneal Metastasis
  40. Surgical management of pancreatic neuroendocrine tumors – An EYSAC and E-AHPBA international survey of current practice
  41. Assessment of Intraoperative Scoring Systems for Predicting Cytoreduction Outcome in Peritoneal Metastatic Disease: A Systematic Review and Meta-analysis
  42. Development of a video-based deep learning model for differentiation of malignant and benign lesions during staging laparoscopy: Is the machine better than the expert?
  43. Standardizing eligibility and patient selection for Pressurized Intraperitoneal Aerosol Chemotherapy: A Delphi consensus statement
  44. Patients’ and carers’ views on research priorities in prehabilitation for cancer surgery
  45. Lymphatic spread patterns in young versus elderly patients with stage III colon cancer
  46. Early postoperative systemic inflammatory response as predictor of anastomotic leakage after esophagectomy: a systematic review and meta-analysis
  47. Current practice in assessment and management of malnutrition in surgical oncology practice – An ESSO-EYSAC snapshot analysis
  48. Effects of hyperthermia on cisplatin tissue penetration and gene expression in peritoneal metastases: results from a randomized trial in ovarian cancer
  49. The empty pelvis syndrome: a core data set from the PelvEx collaborative
  50. Beating the empty pelvis syndrome: the PelvEx Collaborative core outcome set study protocol
  51. Development and validation of an UPLC-MS/MS method for the determination of irinotecan (CPT-11), SN-38 and SN-38 glucuronide in human plasma and peritoneal tumor tissue from patients with peritoneal carcinomatosis
  52. Systemic Inflammatory Response and the Noble and Underwood (NUn) Score as Early Predictors of Anastomotic Leakage after Esophageal Reconstructive Surgery
  53. Systemic Inflammatory Response and the Noble and Underwood (Nun) Score as Early Predictors of Anastomotic Leakage after Esophageal Reconstructive Surgery
  54. Preclinical Activity of Two Paclitaxel Nanoparticle Formulations After Intraperitoneal Administration in Ovarian Cancer Murine Xenografts
  55. Hydraulic conductivity of human cancer tissue: A hybrid study
  56. Variations in the definition and perceived importance of positive resection margins in patients with colorectal cancer – an EYSAC international survey
  57. CO2-Driven Nebulization of pH-Sensitive Supramolecular Polymers for Intraperitoneal Hydrogel Formation and the Treatment of Peritoneal Metastasis
  58. 1550P Evaluating the novel combination of pressurized intraperitoneal aerosol chemotherapy-oxaliplatin (PIPAC-OX) as an immunomodulator in combination with systemic nivolumab for gastric cancer peritoneal metastases
  59. Smart hydrogels delivered by high pressure aerosolization can prevent peritoneal adhesions
  60. Empty pelvis syndrome: PelvEx Collaborative guideline proposal
  61. Drug transport modeling in solid tumors: A computational exploration of spatial heterogeneity of biophysical properties
  62. Effects of Hyperthermia and Hyperthermic Intraperitoneal Chemoperfusion on the Peritoneal and Tumor Immune Contexture
  63. Descriptive review of current practices and prognostic factors in patients with ovarian cancer treated by pressurized intraperitoneal aerosol chemotherapy (PIPAC): a multicentric, retrospective, cohort of 234 patients
  64. Research Priorities in Prehabilitation for Patients Undergoing Cancer Surgery: An International Delphi Study
  65. Author response to: Comment on: Correlation between recurrence-free survival and overall survival after upfront surgery for resected colorectal liver metastases
  66. External multicentre validation of pseudomyxoma peritonei PSOGI-Ki67 classification
  67. SHARP risk score: A predictor of poor outcomes in adults admitted for emergency general surgery: A prospective cohort study
  68. Correlation between recurrence-free survival and overall survival after upfront surgery for resected colorectal liver metastases
  69. Reducing the environmental impact of surgery on a global scale: systematic review and co-prioritization with healthcare workers in 132 countries
  70. Randomized controlled trials and alternative study designs in surgical oncology
  71. A preclinical platform for assessing long-term drug efficacy exploiting mechanically tunable scaffolds colonized by a three-dimensional tumor microenvironment
  72. Connecting the macro- and micro-scale properties in human solid tumors: hydraulic conductivity
  73. Morbidity and survival after laparoscopic versus open pancreatoduodenectomy: propensity score matched comparison
  74. Omentoplasty in Patients Undergoing Abdominoperineal Resection After Long-Course Chemoradiation for Locally Advanced and Locally Recurrent Rectal Cancer: A Comparative Single-Institution Cohort Study
  75. Electromotive Enhanced Drug Administration in Oncology: Principles, Evidence, Current and Emerging Applications
  76. Interstitial fluid pressure as an emerging biomarker in solid tumors
  77. Phase I study of intraperitoneal aerosolized nanoparticle albumin based paclitaxel (NAB-PTX) for unresectable peritoneal metastases
  78. Integration of Genomic Biology Into Therapeutic Strategies of Gastric Cancer Peritoneal Metastasis
  79. The impact of surgical delay on resectability of colorectal cancer: An international prospective cohort study
  80. Optimization of intraperitoneal aerosolized drug delivery using computational fluid dynamics (CFD) modeling
  81. Incidence of lymph node recurrence after primary surgery for non-metastatic colon cancer: A systematic review
  82. Nanoparticle mediated targeting of toll-like receptors to treat colorectal cancer
  83. Consensus statement for treatment protocols in pressurized intraperitoneal aerosol chemotherapy (PIPAC)
  84. Contemporary Management of Locally Advanced and Recurrent Rectal Cancer: Views from the PelvEx Collaborative
  85. Patient‐reported outcomes after pelvic exenteration for colorectal cancer: A systematic review
  86. Biomechanical aspects of the normal and cancer-associated lymphatic system
  87. Anatomical and temporal patterns of lymph node metastasis in colorectal cancer
  88. Quality of Life after Minimally Invasive Esophagectomy: A Cross-Sectional Study
  89. Primary and metastatic peritoneal surface malignancies
  90. Exploring high pressure nebulization of Pluronic F127 hydrogels for intraperitoneal drug delivery
  91. The Feasibility of Pressurised Intraperitoneal Aerosolised Virotherapy (PIPAV) to Administer Oncolytic Adenoviruses
  92. Optimization of Intraperitoneal Aerosolized Drug Delivery: A Computational Fluid Dynamics (CFD) and Experimental Study
  93. The impact of PRODIGE 7 on the current worldwide practice of CRS-HIPEC for colorectal peritoneal metastases: A web-based survey and 2021 statement by Peritoneal Surface Oncology Group International (PSOGI)
  94. Consensus guidelines for pressurized intraperitoneal aerosol chemotherapy: Technical aspects and treatment protocols
  95. Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study
  96. Preclinical In Vivo-Models to Investigate HIPEC; Current Methodologies and Challenges
  97. Hyperthermic Intraperitoneal Chemotherapy: A Critical Review
  98. Incidentally found mucinous epithelial tumors of the appendix with or without pseudomyxoma peritonei: diagnostic and therapeutic algorithms based on current evidence
  99. Intraperitoneal aerosolized nanoparticle albumin based paclitaxel (NAB-PTX) for irresectable peritoneal metastases: A first in human phase I study.
  100. Intraperitoneal EpCAM-Targeted Immunotoxin: A First Step Towards Engineering the Immune Environment in Colorectal Peritoneal Metastases?
  101. Hyperthermic Intraperitoneal Chemotherapy: A Critical Review
  102. Pressurized intraperitoneal aerosol chemotherapy in peritoneal carcinomatosis: is it all up in the air?
  103. The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery
  104. Trace amounts of irinotecan found in the blood of a surgeon after performing HIPEC: what does it imply?
  105. The impact of molecular profile on the lymphatic spread pattern in stage III colon cancer
  106. Current practice and perceptions of safety protocols for the use of intraperitoneal chemotherapy in the operating room: results of the IP-OR international survey
  107. Impact of low anterior resection syndrome (LARS) on the quality of life and treatment options of LARS – A cross sectional study
  108. Society of Surgical Oncology SSO 2021 – International Conference on Surgical Cancer Care
  109. Debulking and HIPEC for ovarian cancer: effects of perfusion temperature on morbidity and cisplatin pharmacokinetics
  110. Electrostatic precipitation pressurized intraperitoneal aerosol chemotherapy (ePIPAC): Finding the optimal electrical potential
  111. Combined liver resection and cytoreductive surgery with HIPEC for metastatic colorectal cancer: Results of a worldwide analysis of 565 patients from the Peritoneal Surface Oncology Group International (PSOGI)
  112. Current practice of pressurized intraperitoneal aerosol chemotherapy (PIPAC): Still standardized or on the verge of diversification?
  113. The Delphi and GRADE methodology used in the PSOGI 2018 consensus statement on Pseudomyxoma Peritonei and Peritoneal Mesothelioma
  114. PKPD Modeling and Dosing Considerations in Advanced Ovarian Cancer Patients Treated with Cisplatin-Based Intraoperative Intraperitoneal Chemotherapy
  115. Synergy between Intraperitoneal Aerosolization (PIPAC) and Cancer Nanomedicine: Cisplatin-Loaded Polyarginine-Hyaluronic Acid Nanocarriers Efficiently Eradicate Peritoneal Metastasis of Advanced Human Ovarian Cancer
  116. Intraperitoneal chemotherapy for peritoneal metastases: an expert opinion
  117. Targeting the Tumor Microenvironment in Colorectal Peritoneal Metastases
  118. Heating technology for malignant tumors: a review
  119. Intraperitoneal aerosolized drug delivery: Technology, recent developments, and future outlook
  120. Albumin-based cancer therapeutics for intraperitoneal drug delivery: a review
  121. Establishment and characterization of a cell line and patient-derived xenograft (PDX) from peritoneal metastasis of low-grade serous ovarian carcinoma
  122. Aerosolization of Nanotherapeutics as a Newly Emerging Treatment Regimen for Peritoneal Carcinomatosis
  123. A 3D CFD model of the interstitial fluid pressure and drug distribution in heterogeneous tumor nodules during intraperitoneal chemotherapy
  124. A practical risk scale for predicting morbidity and mortality in the emergency general surgical setting: A prospective multi-center study
  125. Is there an oncological interest in the combination of CRS/HIPEC for peritoneal carcinomatosis of HCC? Results of a multicenter international study
  126. HIPEC with oxaliplatin for colorectal peritoneal metastasis: The end of the road?
  127. Use of hyperthermia versus normothermia during intraperitoneal chemoperfusion with oxaliplatin for colorectal peritoneal carcinomatosis: A propensity score matched analysis
  128. Assessment of graft perfusion and oxygenation for improved outcome in esophageal cancer surgery
  129. Cytoreductive surgery and HIPEC improve survival compared to palliative chemotherapy for biliary carcinoma with peritoneal metastasis: A multi-institutional cohort from PSOGI and BIG RENAPE groups
  130. Anorectal symptoms during pregnancy and postpartum: a prospective cohort study
  131. The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: Results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI)
  132. Pharmacokinetics and Tissue Transport of Intraperitoneal Chemotherapy
  133. Intraperitoneal aerosolization of albumin-stabilized paclitaxel nanoparticles (Abraxane™) for peritoneal carcinomatosis – a phase I first-in-human study
  134. The impact of surgical resection of the primary tumor on the development of synchronous colorectal liver metastasis: a systematic review
  135. Intraoperative radiation therapy for rectal cancer and recurrent intra-abdominal sarcomas
  136. Peritoneal Carcinomatosis of Rare Ovarian Origin Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Multi-Institutional Cohort from PSOGI and BIG-RENAPE
  137. Hypoxia imaging with 18F-FAZA PET/CT predicts radiotherapy response in esophageal adenocarcinoma xenografts
  138. Heterocellular 3D scaffolds as biomimetic to recapitulate the tumor microenvironment of peritoneal metastases in vitro and in vivo
  139. Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastases From a Small Bowel Adenocarcinoma: Multi-Institutional Experience
  140. Multicenter comprehensive methodological and technical analysis of 832 pressurized intraperitoneal aerosol chemotherapy (PIPAC) interventions performed in 349 patients for peritoneal carcinomatosis treatment: An international survey study
  141. Long-term survival after multimodality therapy including surgery for metastatic esophageal cancer
  142. Radiotherapy-Activated Cancer-Associated Fibroblasts Promote Tumor Progression through Paracrine IGF1R Activation
  143. Adipose-Derived Mesenchymal Stromal Cells Improve the Healing of Colonic Anastomoses Following High Dose of Irradiation Through Anti-Inflammatory and Angiogenic Processes
  144. Synergy between 5-HT4 receptor stimulation and phosphodiesterase 4 inhibition in facilitating acetylcholine release in human large intestinal circular muscle
  145. Tumour tissue transport after intraperitoneal anticancer drug delivery
  146. Effect of abdominopelvic sepsis on cancer outcome in patients undergoing sphincter saving surgery for rectal cancer
  147. High-Pressure Nebulization as Application Route for the Peritoneal Administration of siRNA Complexes
  148. Frailty as a predictor of mortality in the elderly emergency general surgery patient
  149. Mathematical modeling of intraperitoneal drug delivery: simulation of drug distribution in a single tumor nodule
  150. Occupational safety of pressurized intraperitoneal aerosol chemotherapy (PIPAC)
  151. Improved xenograft efficiency of esophageal adenocarcinoma cell lines through in vivo selection
  152. Nanomedicine-based intraperitoneal therapy for the treatment of peritoneal carcinomatosis — Mission possible?
  153. The VEGFR Inhibitor Cediranib Improves the Efficacy of Fractionated Radiotherapy in a Colorectal Cancer Xenograft Model
  154. Nanoscopic tumor tissue distribution of platinum after intraperitoneal administration in a xenograft model of ovarian cancer
  155. The American Society of Peritoneal Surface Malignancies Multi-Institution evaluation of 1,051 advanced ovarian cancer patients undergoing cytoreductive surgery and HIPEC: An introduction of the peritoneal surface disease severity score
  156. Age and cellular context influence rectal prolapse formation in mice with caecal wall colorectal cancer xenografts
  157. Exploring the HYDRAtion method for loading siRNA on liposomes: the interplay between stability and biological activity in human undiluted ascites fluid
  158. Preclinical activity of melflufen (J1) in ovarian cancer
  159. Assessment of Ovarian Cancer Tumors Treated with Intraperitoneal Cisplatin Therapy by Nanoscopic X-ray Fluorescence Imaging
  160. Genipin-crosslinked gelatin microspheres as a strategy to prevent postsurgical peritoneal adhesions: In vitro and in vivo characterization
  161. Metabolic surgery in patients over 60 years old: short- and long-term results
  162. Data on in vivo selection of SK-OV-3 Luc ovarian cancer cells and intraperitoneal tumor formation with low inoculation numbers
  163. Lifelike Vascular Reperfusion of a Thiel-Embalmed Pig Model and Evaluation as a Surgical Training Tool
  164. Animal models of colorectal peritoneal metastasis
  165. Scoring histological regression in peritoneal carcinomatosis: does it count?
  166. BEV-IP: Perioperative chemotherapy with bevacizumab in patients undergoing cytoreduction and intraperitoneal chemoperfusion for colorectal carcinomatosis
  167. Multicentre study of the learning curve and surgical performance of cytoreductive surgery with intraperitoneal chemotherapy for pseudomyxoma peritonei
  168. Colloidal stability of nano-sized particles in the peritoneal fluid: Towards optimizing drug delivery systems for intraperitoneal therapy
  169. Recent insights into the pathophysiology of omental metastases
  170. Preoperative Enoxaparin Versus Postoperative Semuloparin Thromboprophylaxis in Major Abdominal Surgery
  171. A Model Based Analysis of IPEC Dosing of Paclitaxel in Rats
  172. Neoadjuvant Chemotherapy with Bevacizumab May Improve Outcome after Cytoreduction and Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) for Colorectal Carcinomatosis
  173. Lymphatic spread, nodal count and the extent of lymphadenectomy in cancer of the colon
  174. Surgery, wound healing, and metastasis: Recent insights and clinical implications
  175. Clinical Research in Surgery: Threats and Opportunities
  176. Postmortem Pump-Driven Reperfusion of the Vascular System of Porcine Lungs: Towards a New Model for Surgical Training
  177. Molecular Imaging of Tumor-Associated Angiogenesis Using a Novel Magnetic Resonance Imaging Contrast Agent Targeting αvβ3 Integrin
  178. Intraperitoneal chemotherapy (IPC) for peritoneal carcinomatosis: Review of animal models
  179. Effect of perfusion temperature on glucose and electrolyte transport during hyperthermic intraperitoneal chemoperfusion (HIPEC) with oxaliplatin
  180. Recommendations for reporting outcome results in abdominal wall repair
  181. Standardized added metabolic activity (SAM) IN 18F-FDG PET assessment of treatment response in colorectal liver metastases
  182. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer
  183. Optimization of Drug Delivery Systems for Intraperitoneal Therapy to Extend the Residence Time of the Chemotherapeutic Agent
  184. Clinical procedure for colon carcinoma tissue sampling directly affects the cancer marker-capacity of VEGF family members
  185. Early- and Long-Term Outcome Data of Patients With Pseudomyxoma Peritonei From Appendiceal Origin Treated by a Strategy of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
  186. Endovascular Treatment of an Iatrogenic Perforation of the Internal Iliac Vein
  187. Risk adjusted benchmarking of clinical anastomotic leakage rate after total mesorectal excision in the context of an improvement project
  188. Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases
  189. Development of a Nanocrystalline Paclitaxel Formulation for Hipec Treatment
  190. Risk adjusted benchmarking of abdominoperineal excision for rectal adenocarcinoma in the context of the Belgian PROCARE improvement project
  191. Magnetic Electrospun Fibers for Cancer Therapy
  192. The Treatment of Peritoneal Carcinomatosis of Colorectal Cancer with Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Peroperative Chemotherapy (HIPEC) with Oxaliplatin: A Belgian Multicentre Prospective Phase II Clinical Study
  193. Anastomotic Complications After Ivor Lewis Esophagectomy in Patients Treated With Neoadjuvant Chemoradiation Are Related to Radiation Dose to the Gastric Fundus
  194. Mucinous subtype as prognostic factor in colorectal cancer: a systematic review and meta-analysis
  195. Use of pneumatic nebulization and laser ablation–inductively coupled plasma–mass spectrometry to study the distribution and bioavailability of an intraperitoneally administered Pt-containing chemotherapeutic drug
  196. Innovation in Cancer Imaging
  197. Progress in Rectal Cancer Treatment
  198. Variability of CT Contrast Enhancement in the Pancreas: A Cause for Concern?
  199. Tissue perfusion in pathologies of the pancreas: assessment using 128-slice computed tomography
  200. Flip angle optimization for dynamic contrast-enhanced MRI-studies with spoiled gradient echo pulse sequences
  201. First order correction for T2*-relaxation in determining contrast agent concentration from spoiled gradient echo pulse sequence signal intensity
  202. Assessment of Tumor Vascularization in Pancreatic Adenocarcinoma Using 128-Slice Perfusion Computed Tomography Imaging
  203. Malignant Peritoneal Mesothelioma in a Patient With Li-Fraumeni Syndrome
  204. Assessment of neovascular permeability in a pancreatic tumor model using dynamic contrast-enhanced (DCE) MRI with contrast agents of different molecular weights
  205. Antitumour Efficacy of Two Paclitaxel Formulations for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in an In Vivo Rat Model
  206. Precision analysis of kinetic modelling estimates in dynamic contrast enhanced MRI
  207. Noninvasive Monitoring of Therapy-Induced Microvascular Changes in a Pancreatic Cancer Model Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging with P846, a New Low-Diffusible Gadolinium-Based Contrast Agent
  208. Long-Term Results of a Prospective Study on Laparoscopic Adjustable Gastric Banding for Morbid Obesity
  209. Conversion from Band to Bypass in Two Steps Reduces the Risk for Anastomotic Strictures
  210. Prognostic Value of the Lymph Node Ratio in Stage III Colorectal Cancer: A Systematic Review
  211. Laparoendoscopic Single-Site Gastrectomy for a Gastric GIST Using Double-Bended Instruments
  212. In vivo Toxicity and Bioavailability of Taxol® and a Paclitaxel/β-Cyclodextrin Formulation in a Rat Model During HIPEC
  213. The low-molecular-weight heparin, nadroparin, inhibits tumour angiogenesis in a rodent dorsal skinfold chamber model
  214. Cytoreduction and Hyperthermic Intraperitoneal Chemoperfusion in Women with Heavily Pretreated Recurrent Ovarian Cancer
  215. Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence
  216. Letter 1: Randomized clinical trial comparing laparoscopic and open surgery in patients with rectal cancer (Br J Surg2009; 96: 982-989)
  217. Combined Effect of EPO and Radiotherapy on the Expression of Endogenous Molecular Markers of Tumor Metabolism and Metastasis
  218. An Unusual Post Gastrectomy Complication
  219. Preoperative chemoradiationversusradiation alone for stage II and III resectable rectal cancer: A systematic review and meta-analysis
  220. Total vs Partial Fundoplication in the Treatment of Gastroesophageal Reflux Disease
  221. In vitro cytotoxicity of paclitaxel/β-cyclodextrin complexes for HIPEC
  222. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer
  223. Peritoneal minimal residual disease in colorectal cancer: mechanisms, prevention, and treatment
  224. Attempted Suicide by Auto-Injection of Polyurethane (PU) Foam: Report of a Case
  225. Therapeutic Decision-Making in Endoscopically Unmanageable Nonvariceal Upper Gastrointestinal Hemorrhage
  226. Use of Laparoscopy for Rectal Cancer: A Word of Caution
  227. Safety and Efficacy of Hyperthermic Intraperitoneal Chemoperfusion with High-Dose Oxaliplatin in Patients with Peritoneal Carcinomatosis
  228. Paclitaxel/β-cyclodextrin complexes for hyperthermic peritoneal perfusion – Formulation and stability
  229. Recombinant human erythropoietin α modulates the effects of radiotherapy on colorectal cancer microvessels
  230. Neoadjuvant Chemoradiation Versus Hyperfractionated Accelerated Radiotherapy in Locally Advanced Rectal Cancer
  231. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer
  232. Pre-operative combined modality therapy in the management of locally advanced rectal cancer
  233. Noninvasive monitoring of radiotherapy-induced microvascular changes using dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) in a colorectal tumor model
  234. Prospectively Randomized Trial Using Perioperative Low-dose Octreotide to Prevent Organ-related and General Complications after Pancreatic Surgery and Pancreatico-jejunostomy
  235. One- to Three-Year Results of Gastric Banding on Secondary Complications of Morbid Obesity in 625 Patients
  236. Functional Outcome Following Colon Interposition in Total Pharyngoesophagectomy with or without Laryngectomy
  237. The beneficial effects of supplementary glutamine on experimental irradiated colonic anastomosis; histological and morphological evaluation
  238. Surgical Treatment of Severe Obesity With a Low-Pressure Adjustable Gastric Band
  239. Determination of the K adsorption site on Fe() with XSW
  240. Influence of preoperative combined radiochemotherapy on surgical outcome and colonic anastomotic healing: experimental study in the rat
  241. The Swedish Laparoscopic Adjustable Gastric Banding for Morbid Obesity
  242. Influence of preoperative high-dose radiotherapy on postoperative outcome and colonic anastomotic healing
  243. Healing of experimental colonic anastomoses: Effects of combined preoperative high-dose radiotherapy and intraperitoneal 5-fluorouracil
  244. Authors' reply
  245. Das anpassbare Silicon Gastric Banding (ASGB, Bioenterics®) und das Schwedische anpassbare Gastric Banding (SAGB, Obtech®) zur Behandlung der morbiden Obesitas
  246. Hyperthermic intraperitoneal chemoperfusion in the treatment of locally advanced intra-abdominal cancer
  247. Morphology and composition of Au films on Si(100)
  248. Surgeons and the Internet
  249. Ultrathin Au layers on Si(100): surface silicide formation at room temperature
  250. Domain structure, segregation and morphology of the Pt3Sn(111) surface
  251. K adsorption on Fe(100) studied by X-ray standing waves
  252. Non-operative management of a splenic laceration in a patient with the Proteus syndrome.
  253. Substitutional adsorption of K on Fe(100)
  254. Caesium diffusion in sodium borosilicate glass studied by low-energy ion scattering